Clinical Experience with Aurora Kinase Inhibitors: A Review

被引:83
作者
Boss, David S. [1 ]
Beijnen, Jos H. [1 ,2 ,3 ]
Schellens, Jan H. M. [1 ,2 ]
机构
[1] Netherlands Canc Inst, Div Clin Pharmacol, Dept Med Oncol, NL-1066 CX Amsterdam, Netherlands
[2] Univ Utrecht, Fac Sci, Dept Pharmaceut Sci, Sect Biomed Anal,Div Drug Toxicol, Utrecht, Netherlands
[3] Slotervaart Hosp, Dept Pharm & Pharmacol, Amsterdam, Netherlands
关键词
Aurora kinase; Mitosis; Targeted therapy; Drug development; Clinical trial; SMALL-MOLECULE INHIBITOR; CHROMOSOMAL PASSENGER COMPLEX; SPINDLE-ASSEMBLY CHECKPOINT; HISTONE H3 PHOSPHORYLATION; SUPPRESSES TUMOR-GROWTH; LEUKEMIA CELL-LINES; B-KINASE; A KINASE; MITOTIC PHOSPHORYLATION; DOWN-REGULATION;
D O I
10.1634/theoncologist.2009-0019
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
The aurora kinase family of serine/threonine kinases comprises three members, designated auroras A, B, and C. Auroras A and B are essential components of the mitotic pathway, ensuring proper chromosome assembly, formation of the mitotic spindle, and cytokinesis. The role of aurora C is less clear. Overexpression of aurora A and B has been observed in several tumor types, and has been linked with a poor prognosis of cancer patients. Several small molecules targeting aurora kinases A and B or both have been evaluated preclinically and in early phase I trials. In this review we aim to summarize the most recent advances in the development of aurora kinase inhibitors, with a focus on the clinical data. The Oncologist 2009; 14: 780-793
引用
收藏
页码:780 / 793
页数:14
相关论文
共 125 条
[1]
Essential roles of Drosophila inner centromere protein (INCENP) and aurora B in histone H3 phosphorylation, metaphase chromosome alignment, kinetochore disjunction, and chromosome segregation [J].
Adams, RR ;
Maiato, H ;
Earnshaw, WC ;
Carmena, M .
JOURNAL OF CELL BIOLOGY, 2001, 153 (04) :865-879
[2]
Effects of the Aurora kinase inhibitor VX-680 on anaplastic thyroid cancer-derived cell lines [J].
Arlot-Bonnemains, Yannick ;
Baldini, Enke ;
Martin, Benedicte ;
Delcros, Jean-Guy ;
Toller, Matteo ;
Curcio, Francesco ;
Ambesi-Impiombato, Francesco S. ;
D'Armiento, Massimino ;
Ulisse, Salvatore .
ENDOCRINE-RELATED CANCER, 2008, 15 (02) :559-568
[3]
PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer [J].
Carpinelli, Patrizia ;
Ceruti, Roberta ;
Giorgini, Maria Laura ;
Cappella, Paolo ;
Gianellini, Laura ;
Croci, Valter ;
Degrassi, Anna ;
Texido, Gernma ;
Rocchetti, Maurizio ;
Vianello, Paola ;
Rusconi, Luisa ;
Storici, Paola ;
Zugnoni, Paola ;
Arrigoni, Claudio ;
Soncini, Chiara ;
Alli, Cristina ;
Patton, Veronica ;
Marsiglio, Aurelio ;
Ballinari, Dario ;
Pesenti, Enrico ;
Fancelli, Daniele ;
Moll, Jurgen .
MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) :3158-3168
[4]
Aurora kinase inhibitors: identification and preclinical validation of their biomarkers [J].
Carpinelli, Patrizia ;
Moll, Juergen .
EXPERT OPINION ON THERAPEUTIC TARGETS, 2008, 12 (01) :69-80
[5]
CERVANTES A, 2008, EUROPEAN J CANC S, V6
[6]
Cervantes-Ruiperez A, 2009, J CLIN ONCOL, V27
[7]
Structural basis for potent inhibition of the Aurora kinases and a T3151 multi-drug resistant mutant form of Abl kinase by VX-680 [J].
Cheetham, G. M. T. ;
Charlton, P. A. ;
Golec, J. M. C. ;
Pollard, J. R. .
CANCER LETTERS, 2007, 251 (02) :323-329
[8]
Association between aurora-a kinase polymorphisms and age of onset of hereditary nonpolyposis colorectal cancer in a Caucasian population [J].
Chen, Jinyun ;
Sen, Subrata ;
Amos, Christopher I. ;
Wei, Chongjuan ;
Jones, J. Shawn ;
Lynch, Patrick ;
Frazier, Marsha L. .
MOLECULAR CARCINOGENESIS, 2007, 46 (04) :249-256
[9]
Suppression of the STK15 oncogenic activity requires a transactivation-independent p53 function [J].
Chen, SS ;
Chang, PC ;
Cheng, YW ;
Tang, FM ;
Lin, YS .
EMBO JOURNAL, 2002, 21 (17) :4491-4499
[10]
Aurora A: Target invalidated? [J].
Cochran, Andrea G. .
CHEMISTRY & BIOLOGY, 2008, 15 (06) :525-526